Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty products, and OTC pharmaceutic...
| Metric Name | Value | Trend | |
|---|---|---|---|
| Dividend Yield | 0.2% | ||
| P/E Ratio | -211.4x | ||
| Revenue | 139.6 B | ||
| Net Income to Company | -1.715 B |
| GLENMARK | Peers | Sector | |
|---|---|---|---|
Market Cap | 423.2 B | 409.2 B | 5.174 B |
Price % of 52 Week High | 81.9% | 76.5% | 59.9% |
Dividend Yield | 0.2% | 0.9% | 0.0% |
Shareholder Yield | 8.2% | 1.1% | -0.7% |
1 Year Price Total Return | 47.8% | 8.7% | -14.1% |
Beta (5 Year) | 0.67 | 0.43 | 0.64 |
| (presentment in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Mar-23 | Mar-24 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 116,556 | 126,454 | 139,608 | 25,067 | 33,876 |
| Operating Income | 11,382 | 14,457 | 26,148 | (3,557) | 4,775 |
| Net Profit | 2,972 | (15,017) | (1,758) | (3,514) | 3,480 |
| Diluted EPS | -6.01 | -67.30 | -7.10 | -16.66 | 12.33 |
| EBITDA | 14,289 | 18,297 | 30,687 | (2,830) | 5,735 |
| Balance Sheet | |||||
| Cash & ST Invest. | 11,683 | 16,641 | 18,202 | 11,240 | 18,202 |
| Current Assets | 107,255 | 74,281 | |||
| Total Assets | 193,717 | 143,586 | |||
| Current Liabilities | 51,051 | 58,186 | |||
| Total Liabilities | 95,324 | 65,111 | |||
| Total Equity | 98,393 | 78,475 | 84,455 | 97,357 | 84,455 |
| Total Debt | 46,079 | 12,309 | 17,808 | 51,817 | 17,808 |
| Cash Flow Statement | |||||
| Cash Flow Operations | 6,254 | (2,654) | |||
| Cash From Investing | (5,285) | 45,609 | |||
| Cash From Financing | (775) | (39,061) | |||
| Free Cash Flow | 176 | (11,638) | (20,772) | 0.00 | - |